Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

Like ALS, Alzheimer's disease also results from misfolded proteins that damage brain health. Rather than treating symptoms from specific diseases, NU-9 instead addresses the underlying mechanisms of ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

The trial is enrolling people as young as 18 who have few or no detectable Alzheimer's-related molecular changes in their brains, up to 25 years before the expected onset of dementia symptoms, to ...

“This blood test clearly identifies Alzheimer’s tau tangles, which is our best biomarker measure of Alzheimer’s symptoms and dementia,” co-senior author Dr. Randall Bateman, a professor of neurology ...

An innovative at-home smell test may detect Alzheimer’s disease years before traditional symptoms emerge ... a number that’s expected to grow to 13.9 million by 2060. The condition is ...

Early symptoms for Alzheimer’s disease typically appear after age 60 ... The number of people living with Alzheimer’s is projected to double from 6.9 million in 2020 to nearly 14 million ...

An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in their 40s or 50s, according to new findings from ongoing research now ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based ...

The tests help doctors diagnose the neurodegenerative condition in people with symptoms but don't indicate the degree of impairment in thinking or memory due to Alzheimer’s dementia. Current ...